

**UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION

MDL No. 2724

16-md-2724

The Honorable Cynthia M. Rufe

RULE 7.1 DISCLOSURE STATEMENT OF SANDOZ INC.

Pursuant to Federal Rule of Civil Procedure 7.1, the undersigned attorneys of record for defendant Sandoz Inc. (“Sandoz”) state that Sandoz is an indirect, wholly owned subsidiary of Novartis AG, a publicly held company, the shares of which are traded on the SIX Swiss Exchange under the ticker symbol NOVN and whose American Depositary Shares are publicly traded on the New York Stock Exchange under the ticker symbol NVS. There are no publicly traded companies between Sandoz and Novartis AG.

Dated: May 24, 2017

/s/ Saul P. Morgenstern

Saul P. Morgenstern

Margaret A. Rogers

ARNOLD & PORTER KAYE SCHOLER LLP

250 West 55th Street

New York, New York 10019

Tel.: (212) 836-8000

Fax: (212) 836-8689

saoul.morgenstern@apks.com

margaret.rogers@apks.com

Laura S. Shores

ARNOLD & PORTER KAYE SCHOLER LLP

601 Massachusetts Avenue, NW

Washington, DC 20001

Tel.: (202) 942-5000

Fax: (202) 942-5999

laura.shores@apks.com

Attorneys for Defendant Sandoz Inc.

CERTIFICATE OF SERVICE

I, Saul P. Morgenstern, certify that on this 24th day of May, 2017, a copy of the Corporate Disclosure Statement for Sandoz Inc. was filed electronically with the Clerk of the Panel using the Judicial Panel on Multidistrict Litigation's CM/ECF system for filing and served on counsel via the CM/ECF system.

Respectfully submitted,

Dated: May 24, 2017

/s/ Saul P. Morgenstern

Saul P. Morgenstern